# CX3CL1

Source: https://onco.cc/targets/cx3cl1/  
OnCo record `cx3cl1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CX3CL1 (Fractalkine) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.

## Summary

Chemokine that acts as a ligand for both CX3CR1 and integrins ITGAV:ITGB3 and ITGA4:ITGB1. The CX3CR1-CX3CL1 signalling exerts distinct functions in different tissue compartments, such as immune response, inflammation, cell adhesion and chemotaxis. Regulates leukocyte adhesion and migration processes at the endothelium.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Atezolizumab.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: C-X3-C motif chemokine ligand 1; Fractalkine; C3Xkine; ABCD-3; CXC3C; CXC3; SCYD1
- Tags: cancer-genes-wave
- Symbol: CX3CL1
- Class: other
- Biology: Chemokine that acts as a ligand for both CX3CR1 and integrins ITGAV:ITGB3 and ITGA4:ITGB1. The CX3CR1-CX3CL1 signalling exerts distinct functions in different tissue compartments, such as immune response, inflammation, cell adhesion and chemotaxis. Regulates leukocyte adhesion and migration processes at the endothelium. Can activate integrins in both a CX3CR1-dependent and CX3CR1-independent manner. In the presence of CX3CR1, activates integrins by binding to the classical ligand-binding site (site 1) in integrins. In the absence of CX3CR1, binds to a second site (site 2) in integrins which is distinct from site 1 and enhances the binding of other integrin ligands to site 1. Location: Cell membrane; Secreted (UniProt). Locus 16q21 (HGNC).
- Where found: Non-small-cell lung cancer: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:10647: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10647
- UniProt P78423: https://www.uniprot.org/uniprotkb/P78423/entry
- NCBI Gene 6376: https://www.ncbi.nlm.nih.gov/gene/6376
- Ensembl ENSG00000006210: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000006210

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/cx3cl1.json